Commercial-Ready Product with International Patent Filed
CQ1 (Mentabinol®) – As per CanaQuest’s September 17, 2019, press release, this game-changing discovery, Mentabinol®, protects consumers from acute & long-term negative psychiatric side effects of THC intake. This formulation utilizing Food-Grade Botanical Extract “BX” and extracted THC oil from the marijuana “MJ” plant addresses four major problems resulting from consuming THC for an extended time.
The application of Mentabinol® in pre-clinical trials at Western University have demonstrated:
- Reversal of depression-like and schizophrenia related symptom effects;
- Complete blockage of memory impairment;
- Complete blockage of hyperactive activity;
- Complete blockage of gene vulnerability.
Mentabinol® provides an alternative to Opioids.
The discovery was made by a research team led by Dr. Steven Laviolette, neuroscientist, at Western University, leading one of the two sponsored research programs that CanaQuest currently has with prominent Canadian universities.
.
.
Formulated Products under Development
CQ2 – CBD with other Botanical Extracts formulated to treat: anxiety, depression, schizophrenia, PTSD (chronic stress induced), pain and addiction.
CQ3 – New Cannabinoids with other Botanical Extracts – an expansion of the research around the novel formulations utilising other cannabinoids in addition to THC and CBD. This is expected to reveal specialised applications for targeted therapies in specific mental health symptom clusters.
CQ4 – CBD with other Botanical Extracts – mitigation of the spread of cancerous tumors.
.